Axsome Therapeutics Inc.
Axsome Therapeutics Settles AUVELITY Patent Litigation with Teva Pharmaceuticals
Summary
On February 10, 2025, Axsome Therapeutics, Inc. announced the resolution of its patent litigation with Teva Pharmaceuticals over Axsome's AUVELITY product. Under the settlement agreement, Axsome will grant Teva a license to sell a generic version of AUVELITY starting on or after March 31, 2039 if pediatric exclusivity is granted, or on or after September 30, 2038 if no pediatric exclusivity is granted, subject to FDA approval and customary conditions. The agreement resolves all ongoing litigation between the two companies. The settlement is pending review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement